Inactive Instrument

Lifestyle Delivery Systems Inc Stock price Canadian Securities Exchange

Equities

CA53224Y1043

Pharmaceuticals

Sales 2021 432K 319K Sales 2022 * - Capitalization 18.35M 13.55M
Net income 2021 -37M -27.33M Net income 2022 * - EV / Sales 2021 254 x
Net cash position 2021 843K 623K Net cash position 2022 * - 0 EV / Sales 2022 * -
P/E ratio 2021
-3.21 x
P/E ratio 2022 *
-
Employees -
Yield 2021 *
-
Yield 2022 *
-
Free-Float 99.7%
More Fundamentals * Assessed data
Dynamic Chart
Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Core One Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Core One Labs Inc. announced that it has received CAD 0.2 million in funding CI
Core One Labs Inc. announced that it expects to receive CAD 1 million in funding CI
Core One Labs Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer?s and Parkinson's Disease CI
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023 CI
Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer?s and Parkinson?s Disease CI
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process MT
Core One's Vocan Files International Patent For Breakthrough Proprietary Biosynthetic Psilocybin Production Method MT
Core One Labs Inc. Applauds FDA's Draft Guidance on Clinical Trials for Psychedelic Drugs CI
Core One Labs Says in Talks with Multiple Companies to Supply Psilocybin; COOL Gained 15% on Friday MT
Core One Labs Inc. in Talks with Multiple Companies to Supply Psilocybin CI
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization MT
Core One Labs Completes Synthetic Production of Psilocin at GMP Certified Manufacturing Facility; Surges Nearly 26% in Frankfurt Trading MT
More news
Managers TitleAgeSince
Chief Executive Officer 34 -
Director of Finance/CFO 46 20-08-18
Chief Tech/Sci/R&D Officer - 21-05-04
Members of the board TitleAgeSince
Director of Finance/CFO 46 20-08-18
Chairman 75 21-01-05
Director/Board Member 56 21-01-26
More insiders
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics.
More about the company
  1. Stock
  2. Equities
  3. Stock Core One Labs Inc.
  4. Stock Lifestyle Delivery Systems Inc - Canadian Securities Exchange